NovaBridge Biosciences (NBP) Form 6-K — Oct 28, 2026
NovaBridge Biosciences (NASDAQ: NBP) announced the appointment of Chuck Silberstein, M.D., M.B.A., CFA as Chief Financial Officer, effective November 2, 2026. He succeeds Kyler Lei, who resigned effective October 30, 2026, with the filing stating the resignation was not due to any disagreement with the Company. Dr. Silberstein brings over 25 years of biotech and capital markets experience, including CFO roles at GentiBio and Applied Therapeutics, business development leadership at Allergan, and healthcare investing at J.P.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.